Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Pirtobrutinib is making a case for first-line use in CLL/SLL. Pooled data from two phase 3 trials (BRUIN CLL-313 and -314) showed a 93.3% overall response rate and impressive 24-month survival outcomes in treatment-naïve patients. The drug's safety profile was also favorable, with low rates of serious side effects and treatment discontinuations.
Pirtobrutinib, a non-covalent BTK inhibitor currently approved for previously treated CLL/SLL, is showing strong promise as a first-line option. Pooled data from the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, presented at the SOHO 2026 Annual Meeting, revealed consistently high efficacy across 253 treatment-naïve patients with a median age of 66 years.
The results paint an encouraging picture: median PFS and OS were not yet reached after nearly 2.5 years of follow-up, and the safety profile closely mirrored what's been seen in previously treated populations — with notably low rates of atrial fibrillation and hypertension, two common concerns with BTK inhibitors.
By the Numbers:
Why it matters: These findings could support expanding pirtobrutinib's use to the front-line CLL/SLL setting, potentially offering patients a highly effective and well-tolerated alternative to existing first-line therapies. The trials were sponsored by Eli Lilly and Company.
